Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
Ann Jeffers, Wenyi Qin, Shuzi Owens, Kathleen B Koenig, Satoshi Komatsu, Francis J Giles, Daniel M Schmitt, Steven Idell, Torry A Tucker, Ann Jeffers, Wenyi Qin, Shuzi Owens, Kathleen B Koenig, Satoshi Komatsu, Francis J Giles, Daniel M Schmitt, Steven Idell, Torry A Tucker
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of 3 years after diagnosis. Although the etiology of IPF is unknown, it is characterized by extensive alveolar epithelial cell apoptosis and proliferation of myofibroblasts in the lungs. While the origins of these myofibroblast appear to be diverse, fibroblast differentiation contributes to expansion of myofibroblasts and to disease progression. We found that agents that contribute to neomatrix formation and remodeling in pulmonary fibrosis (PF); TGF-β, Factor Xa, thrombin, plasmin and uPA all induced fibroblast/myofibroblast differentiation. These same mediators enhanced GSK-3β activation via phosphorylation of tyrosine-216 (p-Y216). Inhibition of GSK-3β signaling with the novel inhibitor 9-ING-41 blocked the induction of myofibroblast markers; α-SMA and Col-1 and reduced morphological changes of myofibroblast differentiation. In in vivo studies, the progression of TGF-β and bleomycin mediated PF was significantly attenuated by 9-ING-41 administered at 7 and 14 days respectively after the establishment of injury. Specifically, 9-ING-41 treatment significantly improved lung function (compliance and lung volumes; p < 0.05) of TGF-β adenovirus treated mice compared to controls. Similar results were found in mice with bleomycin-induced PF. These studies clearly show that activation of the GSK-3β signaling pathway is critical for the induction of myofibroblast differentiation in lung fibroblasts ex vivo and pulmonary fibrosis in vivo. The results offer a strong premise supporting the continued investigation of the GSK-3β signaling pathway in the control of fibroblast-myofibroblast differentiation and fibrosing lung injury. These data provide a strong rationale for extension of clinical trials of 9-ING-41 to patients with IPF.
Conflict of interest statement
D.M. Schmitt and F.J. Giles are employees of Actuate Therapeutics Inc. and have equity interest in Actuate Therapeutics Inc. No potential conflicts of interest were disclosed by the other authors.
Figures
References
- Ghatak S, et al. Transforming growth factor beta1 (TGFbeta1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. The Journal of biological chemistry. 2017;292:10490–10519. doi: 10.1074/jbc.M116.752469.
- Rangarajan S, et al. Novel Mechanisms for the Antifibrotic Action of Nintedanib. American journal of respiratory cell and molecular biology. 2016;54:51–59. doi: 10.1165/rcmb.2014-0445OC.
- Kandhare AD, Mukherjee A, Ghosh P, Bodhankar SL. Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. EXCLI J. 2016;15:636–651.
- Hecker L, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Science translational medicine. 2014;6:231ra247. doi: 10.1126/scitranslmed.3008182.
- Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells, tissues, organs. 2007;185:73–84. doi: 10.1159/000101306.
- Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. Journal of cell science. 2003;116:1175–1186. doi: 10.1242/jcs.00384.
- Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. American journal of physiology. Gastrointestinal and liver physiology. 2002;283:G204–211. doi: 10.1152/ajpgi.00016.2002.
- Hoeflich KP, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86–90. doi: 10.1038/35017574.
- Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 1993;12:803–808. doi: 10.1002/j.1460-2075.1993.tb05715.x.
- Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. The EMBO journal. 1990;9:2431–2438. doi: 10.1002/j.1460-2075.1990.tb07419.x.
- Bhat RV, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:11074–11079. doi: 10.1073/pnas.190297597.
- Tucker, T. et al. Myocardin is Involved in Mesothelial-Mesenchymal Transition of Human Pleural Mesothelial Cells. American journal of respiratory cell and molecular biology (2019).
- Baarsma HA, et al. Glycogen synthase kinase-3 (GSK-3) regulates TGF-beta(1)-induced differentiation of pulmonary fibroblasts. British journal of pharmacology. 2013;169:590–603. doi: 10.1111/bph.12098.
- Shin HS, et al. Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress. Scientific reports. 2017;7:5690. doi: 10.1038/s41598-017-05836-6.
- Xia H, et al. Low alpha(2)beta(1) integrin function enhances the proliferation of fibroblasts from patients with idiopathic pulmonary fibrosis by activation of the beta-catenin pathway. The American journal of pathology. 2012;181:222–233. doi: 10.1016/j.ajpath.2012.03.034.
- Caraci F, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacological research. 2008;57:274–282. doi: 10.1016/j.phrs.2008.02.001.
- Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Molecular cell. 2001;7:1321–1327. doi: 10.1016/S1097-2765(01)00253-2.
- Karmali R, et al. GSK-3beta inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017;8:114924–114934. doi: 10.18632/oncotarget.22414.
- Ugolkov A, et al. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Transl Oncol. 2017;10:669–678. doi: 10.1016/j.tranon.2017.06.003.
- Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anti-cancer drugs. 2018;29:717–724.
- Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019;134:363–373. doi: 10.1182/blood.2018874560.
- Sahin I, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. 2019;20:1047–1056. doi: 10.1080/15384047.2019.1595283.
- Boren J, et al. Inhibition of Glycogen Synthase Kinase 3beta Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia-Mediated Pleural Injury in Mice. The American journal of pathology. 2017;187:2461–2472. doi: 10.1016/j.ajpath.2017.07.007.
- Bergmann C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis. 2011;70:2191–2198. doi: 10.1136/ard.2010.147140.
- Lan A, Qi Y, Du J. Akt2 mediates TGF-beta1-induced epithelial to mesenchymal transition by deactivating GSK3beta/snail signaling pathway in renal tubular epithelial cells. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2014;34:368–382. doi: 10.1159/000363006.
- Liu H, et al. SB216763, a selective small molecule inhibitor of glycogen synthase kinase-3, improves bleomycin-induced pulmonary fibrosis via activating autophagy. Acta Pharmaceutica Sinica B. 2013;3:226–233. doi: 10.1016/j.apsb.2013.05.004.
- Zhang X, Liu Y, Shao R, Li W. Cdc42-interacting protein 4 silencing relieves pulmonary fibrosis in STZ-induced diabetic mice via the Wnt/GSK-3beta/beta-catenin pathway. Exp Cell Res. 2017;359:284–290. doi: 10.1016/j.yexcr.2017.07.018.
- Hummler SC, et al. Targeting glycogen synthase kinase-3beta to prevent hyperoxia-induced lung injury in neonatal rats. American journal of respiratory cell and molecular biology. 2013;48:578–588. doi: 10.1165/rcmb.2012-0383OC.
- Sisson TH, et al. Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. The American journal of pathology. 2015;185:969–986. doi: 10.1016/j.ajpath.2014.12.005.
- Kamata H, et al. KIF5A transports collagen vesicles of myofibroblasts during pleural fibrosis. Scientific reports. 2017;7:4556. doi: 10.1038/s41598-017-04437-7.
- Tucker TA, et al. Organizing empyema induced in mice by Streptococcus pneumoniae: effects of plasminogen activator inhibitor-1 deficiency. Clinical and translational medicine. 2016;5:17. doi: 10.1186/s40169-016-0097-2.
- Mackinnon AC, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine. 2012;185:537–546. doi: 10.1164/rccm.201106-0965OC.
- Williams L, et al. Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice. American journal of respiratory cell and molecular biology. 2012;46:173–179. doi: 10.1165/rcmb.2011-0276OC.
- Tucker TA, et al. Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury. American journal of respiratory cell and molecular biology. 2014;50:316–327.
- Tucker TA, et al. Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells. American journal of respiratory cell and molecular biology. 2012;46:196–206. doi: 10.1165/rcmb.2011-0071OC.
- Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. American journal of respiratory cell and molecular biology. 1992;7:414–426. doi: 10.1165/ajrcmb/7.4.414.
- Jeffers A, et al. Thrombin down-regulates tissue factor pathway inhibitor expression in a PI3K/nuclear factor-kappaB-dependent manner in human pleural mesothelial cells. American journal of respiratory cell and molecular biology. 2015;52:674–682. doi: 10.1165/rcmb.2014-0084OC.
- Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. American journal of physiology. Lung cellular and molecular physiology. 2008;295:L967–975. doi: 10.1152/ajplung.90349.2008.
- Owens S, et al. Mesomesenchymal transition of pleural mesothelial cells is PI3K and NF-kappaB dependent. American journal of physiology. Lung cellular and molecular physiology. 2015;308:L1265–1273. doi: 10.1152/ajplung.00396.2014.
- Lee JM, et al. Involvement of Alveolar Epithelial Cell Necroptosis in Idiopathic Pulmonary Fibrosis Pathogenesis. American journal of respiratory cell and molecular biology. 2018;59:215–224. doi: 10.1165/rcmb.2017-0034OC.
- Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proceedings of the American Thoracic Society. 2006;3:350–356. doi: 10.1513/pats.200601-001TK.
- Fan M, Liu F, Yang Y, Ye Y, Huang G. Phosphorylation of glycogen synthase kinase-3beta induces epithelial mesenchymal transition in human peritoneal mesothelial cells. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2010;35:329–334.
- Jang YH, et al. Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Laboratory investigation; a journal of technical methods and pathology. 2013;93:194–206. doi: 10.1038/labinvest.2012.166.
- Luo L, et al. Small interfering RNA targeting ILK inhibits EMT in human peritoneal mesothelial cells through phosphorylation of GSK3beta. Molecular medicine reports. 2014;10:137–144. doi: 10.3892/mmr.2014.2162.
- Rusai K, Herzog R, Kuster L, Kratochwill K, Aufricht C. GSK-3beta inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response. Cell stress & chaperones. 2013;18:569–579. doi: 10.1007/s12192-013-0410-6.
- Meares GP, Jope RS. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. The Journal of biological chemistry. 2007;282:16989–17001. doi: 10.1074/jbc.M700610200.
- Bijur GN, Jope RS. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport. 2003;14:2415–2419. doi: 10.1097/00001756-200312190-00025.
- Hilliard TS, et al. Glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anti-cancer drugs. 2011;22:978–985.
- Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proceedings of the American Thoracic Society. 2012;9:111–116. doi: 10.1513/pats.201203-023AW.
- Tatler AL, Jenkins G. TGF-beta activation and lung fibrosis. Proceedings of the American Thoracic Society. 2012;9:130–136. doi: 10.1513/pats.201201-003AW.
- Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776–1784. doi: 10.1172/JCI200320530.
Source: PubMed